Shanghai Fosun Pharmaceutical

Shanghai Fosun Pharmaceutical

Verified
Shanghai Fosun Pharmaceutical a leading healthcare company in China

Launch date
Employees
Ownership
Market cap
CNY105.0b
Net debt
CNY34.2b
Firm valuation
$16.9b (Public information from Aug 2022)
Shanghai Shanghai (HQ)

Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues-2.3b3.1b3.6b3.8b4.6b5.3b
% growth--33 %16 %6 %21 %15 %
EBITDA-628m430m734m785m675m838m
% EBITDA margin-27 %14 %21 %21 %15 %16 %
Profit-391m339m415m458m556m701m
% profit margin-17 %11 %12 %12 %12 %13 %
EV / revenue-6.6x2.9x2.7x4.6x3.0x2.6x
EV / EBITDA-24.4x21.1x13.1x22.2x26.5x19.1x
R&D budget98m131m177m423m---
R&D % of revenue-6 %6 %12 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
N/AN/AIPO
Total Funding-

Recent News about Shanghai Fosun Pharmaceutical

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit

Investments by Shanghai Fosun Pharmaceutical

Edit
Breas Medical
ACQUISITION by Shanghai Fosun Pharmaceutical Mar 2017
EOS Imaging
ACQUISITION by Alphatec Spine Dec 2020
Tridem Pharma
ACQUISITION by Shanghai Fosun Pharmaceutical Oct 2017
View 7 more